Flagship explainer
What drives BioXcel Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$69.9M | FY2025 |
| |
| Income before tax | −$69.9M | FY2025 |
|
| Operating income | −$50.5M | FY2025 |
|
| $642000 | FY2025 |
| |
| Ending assets | $44.9M | FY2025 |
|
| Beginning assets | $38.3M | FY2024 |
|
| −$95.5M | FY2025 |
| |
| −$93.1M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001104659-26-036214